| IOVANCE BIOTHERAPEUTICS |
| USA |
| Gesundheit |
| US4622601007 / A2DT49 |
| 2LB (Frankfurt) / IOVA (NASDAQ) |
| FRA:2LB, ETR:2LB, 2LB:GR, NASDAQ:IOVA |
| - |
| https://www.iovance.com/ |
|
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company pioneering the development and commercialization of tumor-infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. The company's approach harnesses the..
>Volltext.. |
| 1208.4 Mio. EUR |
| 998.35 Mio. EUR |
| 223.34 Mio. EUR |
| -297.5 Mio. EUR |
| -331.46 Mio. EUR |
| -0.95 EUR |
| 41.92 Mio. EUR |
| 138.25 Mio. EUR |
| -256.37 Mio. EUR |
| 2.15 |
| 41.52% |
| 7.41% |
| - |
| - |
| - |
| - |
| IOVANCE |
| 16.04.26 |
|
||||
|
||||
|
||||
|